13808-65-6

Usage

Uses

Used in Pharmaceutical Synthesis:
4-BROMO-3-PHENYL-1H-PYRAZOLE is used as a key intermediate in the synthesis of various pharmaceuticals for its versatile reactivity and potential pharmacological activities. It contributes to the development of new drugs with improved therapeutic effects and reduced side effects.
Used in Agrochemical Synthesis:
In the agrochemical industry, 4-BROMO-3-PHENYL-1H-PYRAZOLE is utilized as a building block in the synthesis of agrochemicals, such as pesticides and herbicides. Its unique chemical properties enable the creation of effective and environmentally friendly agrochemicals.
Used in Organic Synthesis Research:
4-BROMO-3-PHENYL-1H-PYRAZOLE serves as a valuable building block in organic synthesis research, allowing chemists to explore new reaction pathways and develop innovative synthetic methods. Its unique structure and reactivity facilitate the synthesis of complex organic molecules with potential applications in various fields.
Used in Medicinal Chemistry Research:
In medicinal chemistry, 4-BROMO-3-PHENYL-1H-PYRAZOLE is employed as a starting material for the design and synthesis of novel bioactive compounds. Its potential pharmacological activities, such as anticonvulsant and analgesic properties, make it an attractive candidate for the development of new drugs with improved therapeutic profiles.
Used in Drug Development:
4-BROMO-3-PHENYL-1H-PYRAZOLE is a subject of interest in drug development due to its potential anticonvulsant and analgesic properties. Researchers are investigating its therapeutic potential for the treatment of various neurological disorders and pain conditions, aiming to develop safer and more effective medications.

Upstream product

• 2458-26-6 3-phenylpyrazole 
• 26033-20-5 3-Phenyl-1H-pyrazole-4-carboxaldehyde 
• 98-80-6 phenylboronic acid 

Downstream Products

• 105994-77-2 4-bromo-1-methyl-5-phenyl-1H-pyrazole 
• 105994-55-6 4-bromo-1-methyl-3-phenyl-1H-pyrazole 
• 1231302-87-6 2-(((1s,4s)-4-((4-(4-chlorophenyl)-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid 
• 1231309-91-3 tert-butyl 2-(((1s,4s)-4-((4-bromo-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate 
• 1231309-89-9 tert-butyl 2-(((1s,4s)-4-((4-bromo-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate 
• 1092565-12-2 2-(3-phenyl-1H-pyrazol-4-yl)-8-(4-pyridinyl)-1,5-naphthyridine 
• 1002334-06-6 1-methyl-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 
• 1238702-09-4 4-bromo-3-phenyl-1-trityl-1H-pyrazole 
• 1092565-13-3 4-bromo-3-phenyl-1-(4-toluenesulfonyl)-1H-pyrazole 
• 59843-34-4 2-(4-bromo-3-phenyl-pyrazol-1-yl)-N,N-dimethyl-propionamide 
• 59843-35-5 2-(4-bromo-5-phenyl-pyrazol-1-yl)-N,N-dimethyl-propionamide 

Relevant academic research and scientific papers

The interplay of hydrogen bonds and halogen bonds in the structure of NH-pyrazoles bearing C-aryl and C-halogen substituents

The behavior in solution and in the solid state of 3(5)-phenyl-1H-pyrazole (7), 3(5)-phenyl-4-chloro-1H-pyrazole (6), 3(5)-phenyl-4-bromo-1H-pyrazole (1), and 3(5)-p-chlorophenyl-4-bromo-1H-pyrazole (8) is discussed in relation to their 3-phenyl (a)/5-phe

The reaction of dimethylalkynylaluminum reagents with trimethylsilyldiazomethane: Original reactivity leading to new α-Silylated Alkynyl Hydrazones

Trimethylsilyl (TMS) diazomethane does not react as a homologating reagent but as a C-electrophilic species with dimethylalkynylaluminum reagents. This unprecedented reactivity enables a simple access to unusual α-silylated alkynyl hydrazones.

Photocatalytic Oxidative Bromination of Electron-Rich Arenes and Heteroarenes by Anthraquinone

The estimated excited oxidation potential of sodium anthraquinone-2-sulfonate (SAS) increases from 1.8 V to about 2.3 V vs SCE by protonation with Br?nsted acids. This increased photooxidation power of protonated anthraquinone was used for the regio-selective oxidative bromination of electron rich (hetero)arenes and drugs in good yield. The mild reaction conditions are compatible with many functional groups, such as double and triple bonds, ketones, amides and amines, hydroxyl groups, carboxylic acids and carbamates. Mechanistic investigations indicate the photooxidation of the arene followed by nucleophilic bromide addition as the likely pathway. (Figure presented.).

A mild halogenation of pyrazoles using sodium halide salts and Oxone

A mild, inexpensive, and operationally simple pyrazole halogenation method utilizing Oxone and sodium halide salts is reported. This work documents 17 examples of alkyl, aryl, allyl, and benzyl substituted 4-chloro and 4-bromopyrazoles, obtained in up to 93% yield. Reactions are performed in water under ambient conditions and generation of organic byproducts is avoided.

Discovery of Potent and Selective RSK Inhibitors as Biological Probes

While the p90 ribosomal S6 kinase (RSK) family has been implicated in multiple tumor cell functions, the full understanding of this kinase family has been restricted by the lack of highly selective inhibitors. A bis-phenol pyrazole was identified from hig

PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN(PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO

Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

Pyridazinone compounds

The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound of formula (I0): wherein R1 represents a substituent, R2 represents a hydrogen atom, or a substituent, R3 represents a hydrogen atom, or a substituent, Ring A represents an aromatic ring which can be substituted, and Ring B represents a 5-membered heteroaromatic ring which can be substituted, or a salt thereof.

NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS

Invented is a method of inhibiting the activity/function of PB kinases using naphthyridine derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of naphthyridine derivatives.